Get the latest Science News and Discoveries

Omalizumab, a recombinant humanized IgG1 monoclonal antibody, reduces allergic reactions to multiple foods in NIH trial. This could expand the amount of different common foods that children with food allergies can safely consume without eliciting an allergic reaction.

None

Related news:

Once reluctant, new NIH chief Monica Bertagnolli has embraced her leading role

NIH advisory group recommends $14,000 boost in postdoc pay

News at a glance: AI rules for Europe, vaccines for Africa, and a union for NIH early-career researchers